Skip to content
2000
Volume 20, Issue 23
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The purpose of this review is to examine human and preclinical data that are relevant to the following hypotheses. The first hypothesis is that deficient CB1R-mediated signaling results in symptoms that mimic those seen in depression. The second hypothesis is that activation of CB1R-mediated signaling results in behavioral, endocrine and other effects that are similar to those produced by currently used antidepressants. The third hypothesis is that conventional antidepressant therapies act through enhanced CB1R mediated signaling. Together the available data indicate that activators of CB1R signaling, particularly inhibitors of fatty acid amide hydrolase, should be considered for clinical trials for the treatment of depression.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/13816128113196660735
2014-05-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/13816128113196660735
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test